ATLANTA and PITTSBURGH – The University of Pittsburgh and Parallel, an organization that’s pioneering human well-being by means of its proprietary cannabinoid manufacturers, science and technology-led innovation, introduced a relationship to determine a scientific analysis program to check medical marijuana. As half of a 10-year settlement, Parallel, by means of Goodblend, its new international retail model, will present University of Pittsburgh an preliminary $three million in unrestricted grants for use for the exploration of the efficacy and security of medical hashish with an preliminary deal with treating sickle cell illness signs. Parallel may also dispense cutting-edge hashish formulations to analysis examine individuals. Subsequent analysis will handle different continual situations, most notably generalized anxiousness issues and continual intractable ache.

The University of Pittsburgh School of Medicine (Pitt) is one of eight Pennsylvania educational analysis universities accepted to conduct scientific analysis in affiliation with the commonwealth’s medical marijuana program. With Pennsylvania’s approval of this medical hashish analysis partnership, Parallel was additionally granted a license for vertically -integrated operations to develop and course of hashish and divulge heart’s contents to six retail areas throughout the state.


“The University of Pittsburgh School of Medicine sees great value in the partnership with Parallel for the residents of the commonwealth and beyond,” mentioned Anantha Shekhar, senior vice chancellor for well being sciences and the John and Gertrude Petersen Dean of the University of Pittsburgh School of Medicine. “Pennsylvania’s medical marijuana law emphasizes the need for rigorous research related to the use of medical cannabis,” Shekhar continued. “Pitt is taking a leadership role in conducting that research and we look forward to advancing the safety and efficacy of cannabis therapies via scientific rigor. Parallel’s focus on the innovation, quality, safety and consistency of its products makes them an ideal partner for Pitt’s research program.”

“Parallel is honored to be the medical cannabis partner of the University of Pittsburgh. Their position as one of the leading global medical research institutions will assist us in advancing our medical understanding of the benefits of cannabinoids in treating a wide spectrum of diseases and conditions,” mentioned William “Beau” Wrigley, Jr., Parallel chief govt officer. “Parallel is pioneering the development of cannabis therapies through strategic partnerships with leading institutions such as the University of Pittsburgh. We believe that research is essential to optimize the targeted benefits of cannabinoids as they hold great promise to replace pharmaceuticals for numerous conditions. We are honored to have been selected to provide the patients of Pennsylvania with our therapies to help improve their well-being.”

Pitt will start its medical marijuana analysis program with a scientific trial in sufferers who are suffering from sickle cell illness (SCD). This program can be led Dr. Laura DeCastro MD, Associate Professor of Medicine and Director of Clinical Translational Research for the Sickle Cell Disease Research Center of Excellence. The trial will examine what function hashish can play in treating the signs of SCD, a pink blood cell dysfunction characterised by anemia and ache as a result of obstruction of blood vessels by inflexible and adhesive pink blood cells. Approximately 100,000 Americans endure from SCD, which is related with a median life expectancy of 45 years and which disproportionately impacts African Americans. About 15% of sickle cell sufferers endure continual ache, which is usually handled with opioids. This class of medicine usually fails to utterly management ache and comes with critical unwanted effects. Pain and different scientific issues are answerable for frequent hospitalizations of these with SCD and lifelong undiscounted well being care prices quantity to almost $1 million per affected person.

“Patients with sickle cell disease and chronic pain have no real alternative to chronic opioid therapy, which has severe limitations and disadvantages,” mentioned Laura DeCastro, MD, MBBS and Pitt affiliate professor of medication, director of benign hematology for the Institute for Transfusion Medicine and UPMC Hillman Cancer Center, and director of Clinical Translational Research for the Sickle Cell Disease Research Center of Excellence. “We are proud to have this opportunity to study potential cannabis treatments for these patients who live in constant debilitating pain.”

“Our partnership with the University of Pittsburgh aligns with our mission of promoting well-being for all and to provide access and treatment options to communities who need it most,” mentioned Wrigley. “SCD is a devastating disease that has impacted many African American families, both medically and financially, and we are hopeful that our research partnership with Pitt will help to improve outcomes through cannabis.”

About the University of Pittsburgh
A nonsectarian, coeducational, state-related, public analysis college based in 1787, the University of Pittsburgh (Pitt) is a member of the distinguished by-invitation-only Association of American Universities and internationally famend as a number one middle of studying and analysis in the humanities, sciences, humanities, professions and well being sciences. Comprising a Pittsburgh campus, which is residence to 16 undergraduate, graduate {and professional} colleges, and 4 Western Pennsylvania regional campuses, Pitt gives practically 500 distinct diploma applications and confers greater than 8,500 levels yearly. Pitt has ranked among the many prime 10 recipients of funding from the National Institutes of Health since 1998 and is ranked among the many prime 10 American analysis universities nationally in phrases of whole federal science and engineering analysis and improvement obligations. For extra info, go to

About Parallel
Parallel is one of the biggest privately held, vertically built-in, multi-state hashish corporations in the world with a mission to pioneer well-being and enhance the standard of life by means of cannabinoids. Parallel owns and operates retail dispensaries in 4 medical and adult-use markets: Surterra Wellness in Florida and Texas; New England Treatment Access (NETA) in Massachusetts, and The Apothecary Shoppe in Nevada. The Company has a various portfolio of top quality, proprietary and licensed shopper manufacturers and merchandise together with Surterra Wellness, Coral Reefer, and Float. Parallel operates roughly 50 retail shops nationwide, together with cultivation and manufacturing websites throughout the 4 states. The Company conducts superior hashish science by means of Molecular Infusions (Mi), a cannabis-based biopharmaceutical firm, and conducts R&D for brand spanking new product improvement in its services in Texas, Massachusetts, Florida, and Budapest, Hungary. Parallel follows rigorous operations and enterprise practices to make sure the standard, security, consistency and efficacy of its merchandise and is constructing its enterprise by following robust values and placing the well-being of its clients and staff first. For extra info:

Source link